VHL and neoplasm: In the end, our recorded risk group (HR = 3.92, p-value = 2.25 × 10−5), tumor stage (HR = 3.47, p-value = 2.80 × 10−6), age (HR = 1.04, p-value = 3.62 × 10−5), and mutation status of VHL (HR = 0.68, p-value = 0.11) remained as independent prognostic biomarkers (Table 3).